Quick Take
Aprea Therapeutics (APRE) intends to raise $75 million in an IPO, according to an amended registration statement.
The company is developing drug treatments for MDS and acute myeloid leukemia.
APRE has achieved impressive Phase 2 trial results for its lead candidate and expects an initial readout for its pivotal Phase 3 trials by the second half of 2020.
For patient life science investors, this biopharma IPO appears promising.
Company & Technology
Boston, Massachusetts-based Aprea was founded in 2003 with a focus on developing cancer therapeutics that activate the reactive mutant